Quest Diagnostics Skeptical Congress Will Pass RESULTS Act in 2025, Firm's Q3 Revenues up 13 Percent
The company noted that if PAMA cuts go into effect at the beginning of next year as scheduled, they would negatively impact its 2026 revenues by around $100 million.
The California-based firm said that its VeriClear EbV MARV Rapid Antigen Test will be used for the detection and differentiation of Ebola and Marburg virus infections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback